Shanghai Fosun Pharmaceutical Group Co Ltd (2196)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 20 Oct 2026
Key indicators
| Last close | HKD 17.08 |
|---|---|
| 52-week range | 14.51 – 25.10 |
| Return, 1 month / 3 months | −0.4% / +3.7% |
| Return, 1 year / 3 years | −31.2% / −0.1% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 34.1% |
| Worst drawdown (1 year) | -38.6% |
| Average daily value traded | 62.07M HKD |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Shanghai Fosun Pharmaceutical Group develops, manufactures and distributes medicines and healthcare products. Its pharmaceutical business covers branded and generic drugs in areas such as anti-infection, cardiovascular, oncology and central nervous system treatments, while it also runs hospitals and medical services and makes medical devices and diagnostics. Customers include hospitals, clinics, pharmacies and distributors, mainly in China, with some international sales. The company is based in Shanghai.
Shanghai Fosun Pharmaceutical Group Co Ltd trades under the code 2196 on the Hong Kong Stock Exchange in Hong Kong, with its price quoted in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Shanghai Fosun Pharmaceutical Group Co Ltd (2196) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 17.08 on 20 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 666 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.2% and over the last three months it rose 3.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -4.7% | ||
| From 52-week high | -28.5% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.7% | ||
| 6-month return | -13.0% | ||
| 12-month return, skipping the last month | -30.9% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 34.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.6% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 62.07M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.0% |
|---|---|
| 1 month | −0.4% |
| 3 months | +3.7% |
| 6 months | −13.0% |
| 1 year | −31.2% |
| 3 years | −0.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 17.20 / 17.92 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.58 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 16 Jul 2026 | HKD 0.4500 |
| 24 Jul 2025 | HKD 0.3500 |
| 26 Jul 2024 | HKD 0.3000 |
| 31 Jul 2023 | HKD 0.4600 |
| 8 Jun 2022 | HKD 0.6600 |
| 7 Jul 2021 | HKD 0.5200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.